

C. Berriez

Sample ID: 2607APO3069.15280
Strain: C. Berriez

Matrix: Plant
Type: Flower - Cured
Source Batch #:

Collected: 07/03/2026 07:32 am
Received: 07/03/2026
Completed: 07/08/2026
Batch #: 1485.C.BERRIEZ
Harvest Date: 07/01/2026

Client
Tru Med
Lic. # 00000079DCUU00478781

Lot #:
Production/Manufacture Date:
Production/Manufacture Method: Indoor



Summary

Test	Date Tested	Result
Batch		Pass
Cannabinoids	07/06/2026	Complete
Terpenes	07/07/2026	Complete
Microbials	07/06/2026	Pass
Pesticides	07/06/2026	Pass
Heavy Metals	07/06/2026	Pass

Cannabinoids by SOP-6

Complete

24.3149 %	ND	28.2967 %	2.9339 %
Total THC	Total CBD	Total Cannabinoids ^(Q3)	Total Terpenes ^(Q3)

Analyte	LOD %	LOQ %	Result %	Result mg/g	Q
THCa		0.1000	26.3634	263.634	
Δ9-THC		0.1000	1.1942	11.942	
Δ8-THC		0.1000	ND	ND	
THCV		0.1000	ND	ND	
CBDa		0.1000	<LOQ	<LOQ	
CBD		0.1000	ND	ND	
CBDVa		0.1000	ND	ND	
CBDV		0.1000	ND	ND	
CBN		0.1000	ND	ND	
CBGa		0.1000	0.7391	7.391	
CBG		0.1000	<LOQ	<LOQ	
CBC		0.1000	ND	ND	
(6aR,9S)-Δ10-THC		0.1000	ND	ND	
(6aR,9R)-Δ10-THC		0.1000	ND	ND	
Total THC			24.3149	243.1494	
Total CBD			ND	ND	
Total			28.2967	282.9676	Q3

Date Tested: 07/06/2026 07:00 am

This CoA's Total THC% is compliant with the July 1st 2026 version of the ruleset.



Anthony Settanni
Anthony Settanni
Lab Director
07/08/2026

Confident LIMS
All Rights Reserved
coa.support@confidentlims.com
(866) 506-5866
www.confidentlims.com



ARIZONA DEPARTMENT OF HEALTH SERVICES' WARNING:

Marijuana use can be addictive and can impair an individual's ability to drive a motor vehicle or operate heavy machinery. Marijuana smoke contains carcinogens and can lead to an increased risk for cancer, tachycardia, hypertension, heart attack, and lung infection. Marijuana use may affect the health of a pregnant woman and the unborn child. Using marijuana during pregnancy could cause birth defects or other health issues to your unborn child;

KEEP OUT OF REACH OF CHILDREN.

The product associated with the CoA has been tested by Apollo Labs using validated state certified testing methodologies as required by Arizona state law. Values reported herein relate only to the specific sample of product submitted by Client for testing. Apollo Labs makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levels of any compounds reported herein. This Certificate shall not be reproduced except in full, without the written approval of Apollo Labs. Testing results were obtained according to requirements in the quality assurance plan in R9-17-404.05, in the applicable standard operating procedure, and in R9-17-404.03 or R9-17-404.04.

C. Berriez

Sample ID: 2607APO3069.15280

Strain: C. Berriez

Matrix: Plant

Type: Flower - Cured

Source Batch #:

Collected: 07/03/2026 07:32 am

Received: 07/03/2026

Completed: 07/08/2026

Batch #: 1485.C.BERRIEZ

Harvest Date: 07/01/2026

Client

Tru Med

Lic. # 00000079DCUU00478781

Lot #:

Production/Manufacture Date:

Production/Manufacture Method: Indoor

Pesticides by SOP-22

Pass

Analyte	LOQ	Limit	Result	Q	Status	Analyte	LOQ	Limit	Result	Q	Status
	PPM	PPM	PPM				PPM	PPM	PPM		
Abamectin	0.2500	0.5000	ND		Pass	Hexythiazox	0.5000	1.0000	ND		Pass
Acephate	0.2000	0.4000	ND		Pass	Imazalil	0.1000	0.2000	ND		Pass
Acetamiprid	0.1000	0.2000	ND		Pass	Imidacloprid	0.2000	0.4000	ND		Pass
Aldicarb	0.2000	0.4000	ND		Pass	Kresoxim Methyl	0.2000	0.4000	ND		Pass
Azoxystrobin	0.1000	0.2000	ND		Pass	Malathion	0.1000	0.2000	ND		Pass
Bifenazate	0.1000	0.2000	ND		Pass	Metalaxyl	0.1000	0.2000	ND		Pass
Bifenthrin	0.1000	0.2000	ND		Pass	Methiocarb	0.1000	0.2000	ND		Pass
Boscalid	0.2000	0.4000	ND		Pass	Methomyl	0.2000	0.4000	ND		Pass
Carbaryl	0.1000	0.2000	ND		Pass	Myclobutanil	0.1000	0.2000	ND		Pass
Carbofuran	0.1000	0.2000	ND		Pass	Naled	0.2500	0.5000	ND		Pass
Chlorantraniliprole	0.1000	0.2000	ND		Pass	Oxamyl	0.5000	1.0000	ND		Pass
Chlorfenapyr	0.5000	1.0000	ND		Pass	Paclobutrazol	0.2000	0.4000	ND		Pass
Chlorpyrifos	0.1000	0.2000	ND		Pass	Permethrins	0.1000	0.2000	ND		Pass
Clofentezine	0.1000	0.2000	ND		Pass	Phosmet	0.1000	0.2000	ND		Pass
Cyfluthrin	0.5000	1.0000	ND		Pass	Piperonyl	1.0000	2.0000	ND		Pass
Cypermethrin	0.5000	1.0000	ND		Pass	Butoxide					
Daminozide	0.5000	1.0000	ND		Pass	Prallethrin	0.1000	0.2000	ND		Pass
Diazinon	0.1000	0.2000	ND		Pass	Propiconazole	0.2000	0.4000	ND		Pass
Dichlorvos	0.0500	0.1000	ND	11	Pass	Propoxur	0.1000	0.2000	ND		Pass
Dimethoate	0.1000	0.2000	ND		Pass	Pyrethrins	0.5000	1.0000	ND		Pass
Ethoprophos	0.1000	0.2000	ND		Pass	Pyridaben	0.1000	0.2000	ND		Pass
Etofenprox	0.2000	0.4000	ND		Pass	Spinosad	0.1000	0.2000	ND		Pass
Etoxazole	0.1000	0.2000	ND		Pass	Spiromesifen	0.1000	0.2000	ND		Pass
Fenoxycarb	0.1000	0.2000	ND		Pass	Spirotetramat	0.1000	0.2000	ND		Pass
Fenpyroximate	0.2000	0.4000	ND		Pass	Spiroxamine	0.2000	0.4000	ND		Pass
Fipronil	0.2000	0.4000	ND		Pass	Tebuconazole	0.2000	0.4000	ND		Pass
Flonicamid	0.5000	1.0000	ND		Pass	Thiacloprid	0.1000	0.2000	ND		Pass
Fludioxonil	0.2000	0.4000	ND		Pass	Thiamethoxam	0.1000	0.2000	ND		Pass
						Trifloxystrobin	0.1000	0.2000	ND		Pass

Date Tested: 07/06/2026 07:00 am



Anthony Settanni

Anthony Settanni
Lab Director
07/08/2026

Confident LIMS
All Rights Reserved
coa.support@confidentlims.com
(866) 506-5866
www.confidentlims.com



ARIZONA DEPARTMENT OF HEALTH SERVICES' WARNING:

Marijuana use can be addictive and can impair an individual's ability to drive a motor vehicle or operate heavy machinery. Marijuana smoke contains carcinogens and can lead to an increased risk for cancer, tachycardia, hypertension, heart attack, and lung infection. Marijuana use may affect the health of a pregnant woman and the unborn child. Using marijuana during pregnancy could cause birth defects or other health issues to your unborn child.

KEEP OUT OF REACH OF CHILDREN.

The product associated with the COA has been tested by Apollo Labs using validated state certified testing methodologies as required by Arizona state law. Values reported herein relate only to the specific sample of product submitted by Client for testing. Apollo Labs makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levels of any compounds reported herein. This Certificate shall not be reproduced except in full, without the written approval of Apollo Labs. Testing results were obtained according to requirements in the quality assurance plan in R9-17-404.05, in the applicable standard operating procedure, and in R9-17-404.03 or R9-17-404.04.

C. Berriez

Sample ID: 2607APO3069.15280

Strain: C. Berriez

Matrix: Plant

Type: Flower - Cured

Source Batch #:

Collected: 07/03/2026 07:32 am

Received: 07/03/2026

Completed: 07/08/2026

Batch #: 1485.C.BERRIEZ

Harvest Date: 07/01/2026

Client

Tru Med

Lic. # 00000079DCUU00478781

Lot #:

Production/Manufacture Date:

Production/Manufacture Method: Indoor

Microbials

Pass

Analyte	Limit	Result	Status	Q
Salmonella SPP by QPCR: SOP-15	Detected/Not Detected in 1g	ND	Pass	
Aspergillus Flavus Aspergillus Fumigatus or Aspergillus Niger by QPCR: SOP-14	Detected/Not Detected in 1g	ND	Pass	
Aspergillus Terreus by QPCR: SOP-14	Detected/Not Detected in 1g	ND	Pass	

Analyte	LOQ	Limit	Result	Status	Q
	CFU/g	CFU/g	CFU/g		
E. Coli by traditional plating: SOP-13	10.0	100.0	< 10 CFU/g	Pass	

Date Tested: 07/06/2026 12:00 am

Mycotoxins by SOP-22

Not Tested

Analyte	LOD	LOQ	Limit	Units	Status	Q
---------	-----	-----	-------	-------	--------	---

Date Tested:

Heavy Metals by SOP-21

Pass

Analyte	LOD	LOQ	Limit	Units	Status	Q
	PPM	PPM	PPM	PPM		
Arsenic	0.1000	0.1330	0.4000	ND	Pass	
Cadmium	0.1000	0.1330	0.4000	ND	Pass	
Lead	0.2500	0.3330	1.0000	ND	Pass	
Mercury	0.0500	0.0660	0.2000	ND	Pass	

Date Tested: 07/06/2026 07:00 am



Anthony Settanni

Anthony Settanni
Lab Director
07/08/2026

Confident LIMS
All Rights Reserved
coa.support@confidentlims.com
(866) 506-5866
www.confidentlims.com



ARIZONA DEPARTMENT OF HEALTH SERVICES' WARNING:

Marijuana use can be addictive and can impair an individual's ability to drive a motor vehicle or operate heavy machinery. Marijuana smoke contains carcinogens and can lead to an increased risk for cancer, tachycardia, hypertension, heart attack, and lung infection. Marijuana use may affect the health of a pregnant woman and the unborn child. Using marijuana during pregnancy could cause birth defects or other health issues to your unborn child;

KEEP OUT OF REACH OF CHILDREN.

The product associated with the COA has been tested by Apollo Labs using validated state certified testing methodologies as required by Arizona state law. Values reported herein relate only to the specific sample of product submitted by Client for testing. Apollo Labs makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levels of any compounds reported herein. This Certificate shall not be reproduced except in full, without the written approval of Apollo Labs. Testing results were obtained according to requirements in the quality assurance plan in R9-17-404.05, in the applicable standard operating procedure, and in R9-17-404.03 or R9-17-404.04.

C. Berriez

Sample ID: 2607APO3069.15280

Strain: C. Berriez

Matrix: Plant

Type: Flower - Cured

Source Batch #:

Collected: 07/03/2026 07:32 am

Received: 07/03/2026

Completed: 07/08/2026

Batch #: 1485.C.BERRIEZ

Harvest Date: 07/01/2026

Client

Tru Med

Lic. # 00000079DCUU00478781

Lot #:

Production/Manufacture Date:

Production/Manufacture Method: Indoor

Terpenes

Analyte	LOQ	Result	Result	Q		Analyte	LOQ	Result	Result	Q
	%	%	mg/g				%	%	mg/g	
β-Caryophyllene	0.0010	0.7378	7.378	Q3		Camphor	0.0010	ND	ND	Q3
D,L-Limonene	0.0010	0.4351	4.351	Q3		Carvone	0.0010	ND	ND	Q3
β-Myrcene	0.0010	0.4092	4.092	Q3		Cedrol	0.0010	ND	ND	Q3
Linalool	0.0010	0.3650	3.650	Q3		cis-Nerolidol	0.0010	ND	ND	Q3
α-Humulene	0.0010	0.1848	1.848	Q3		Eucalyptol	0.0010	ND	ND	Q3
cis-Farnesol	0.0010	0.1818	1.818	Q3		γ-Terpinene	0.0010	ND	ND	Q3
α-Bisabolol	0.0010	0.0985	0.985	Q3		Geraniol	0.0010	ND	ND	Q3
trans-Nerolidol	0.0010	0.0954	0.954	Q3		Geranyl Acetate	0.0010	ND	ND	Q3
β-Pinene	0.0010	0.0916	0.916	Q3		Guaiol	0.0010	ND	ND	Q3
Fenchone	0.0010	0.0901	0.901	Q3		Isoborneol	0.0010	ND	ND	Q3
α-Terpineol	0.0010	0.0809	0.809	Q3		Isobornyl Acetate	0.0010	ND	ND	Q3
α-Pinene	0.0010	0.0489	0.489	Q3		Isopulegol	0.0010	ND	ND	Q3
Caryophyllene Oxide	0.0010	0.0411	0.411	Q3		m-Cymene	0.0010	ND	ND	Q3
trans-beta-Ocimene	0.0010	0.0300	0.300	Q3		Menthol	0.0010	ND	ND	Q3
Camphene	0.0010	0.0125	0.125	Q3		L-Menthone	0.0010	ND	ND	Q3
D,L-Borneol	0.0010	0.0100	0.100	Q3		Nerol	0.0010	ND	ND	Q3
Endo-Fenchyl Alcohol	0.0010	0.0060	0.060	Q3		Nootkatone	0.0010	ND	ND	Q3
Citronellol	0.0010	0.0056	0.056	Q3		o,p-Cymene	0.0010	ND	ND	Q3
Terpinolene	0.0010	0.0039	0.039	Q3		Octyl Acetate	0.0010	ND	ND	Q3
Terpinen-4-ol	0.0010	0.0031	0.031	Q3		Phytane	0.0010	ND	ND	Q3
Sabinene Hydrate	0.0010	0.0025	0.025	Q3		Piperitone	0.0010	ND	ND	Q3
3-Carene	0.0010	ND	ND	Q3		Pulegone	0.0010	ND	ND	Q3
α-Cedrene	0.0010	ND	ND	Q3		Sabinene	0.0010	ND	ND	Q3
α-Phellandrene	0.0010	ND	ND	Q3		Thymol	0.0010	ND	ND	Q3
α-Terpinene	0.0010	ND	ND	Q3		trans-Citral	0.0010	ND	ND	Q3
α-Thujone	0.0010	ND	ND	Q3		Valencene	0.0010	ND	ND	Q3
						Total		2.9339	29.339	

Primary Aromas

 Cinnamon	 Orange	 Hops	 Lavender	 Chamomile
---	---	---	---	--

Date Tested: 07/07/2026 12:00 am
Terpenes analysis is not regulated by AZDHS.




Anthony Settanni
Lab Director
07/08/2026

Confident LIMS
All Rights Reserved
coa.support@confidentlims.com
(866) 506-5866
www.confidentlims.com



ARIZONA DEPARTMENT OF HEALTH SERVICES' WARNING:

Marijuana use can be addictive and can impair an individual's ability to drive a motor vehicle or operate heavy machinery. Marijuana smoke contains carcinogens and can lead to an increased risk for cancer, tachycardia, hypertension, heart attack, and lung infection. Marijuana use may affect the health of a pregnant woman and the unborn child. Using marijuana during pregnancy could cause birth defects or other health issues to your unborn child;

KEEP OUT OF REACH OF CHILDREN.

The product associated with the COA has been tested by Apollo Labs using validated state certified testing methodologies as required by Arizona state law. Values reported herein relate only to the specific sample of product submitted by Client for testing. Apollo Labs makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levels of any compounds reported herein. This Certificate shall not be reproduced except in full, without the written approval of Apollo Labs. Testing results were obtained according to requirements in the quality assurance plan in R9-17-404.05, in the applicable standard operating procedure, and in R9-17-404.03 or R9-17-404.04.

C. Berriez

Sample ID: 2607APO3069.15280

Strain: C. Berriez

Matrix: Plant

Type: Flower - Cured

Source Batch #:

Collected: 07/03/2026 07:32 am

Received: 07/03/2026

Completed: 07/08/2026

Batch #: 1485.C.BERRIEZ

Harvest Date: 07/01/2026

Client

Tru Med

Lic. # 00000079DCUU00478781

Lot #:

Production/Manufacture Date:

Production/Manufacture Method: Indoor

Qualifiers Definitions

Qualifier Notation	Qualifier Description
D1	The limit of quantitation and the sample results were adjusted to reflect sample dilution
I1	The relative intensity of a characteristic ion in a sample analyte exceeded the acceptance criteria in subsection (L)(1) with respect to the reference spectra, indicating interference
L1	When testing for pesticides, fungicides, herbicides, growth regulators, heavy metals, or residual solvents, the percent recovery of a laboratory control sample is greater than the acceptance limits in subsection (K)(2)(c), but the sample's target analytes were not detected above the maximum allowable concentrations in Table 3.1 for the analytes in the sample
M1	The recovery from the matrix spike in subsection (K)(4) was: a. High, but the recovery from the laboratory control sample in subsection (K)(2) was within acceptance criteria
M2	The recovery from the matrix spike in subsection (K)(4) was: b. Low, but the recovery from the laboratory control sample in subsection (K)(2) was within acceptance criteria
M3	The recovery from the matrix spike in subsection (K)(4) was: c. Unusable because the analyte concentration was disproportionate to the spike level, but the recovery from the laboratory control sample in subsection (K)(2) was within acceptance criteria
R1	The relative percent difference for the laboratory control sample and duplicate exceeded the limit in subsection (K)(3), but the recovery in subsection (K)(2) was within acceptance criteria
V1	The recovery from continuing calibration verification standards exceeded the acceptance limits in subsection (J)(1)(b), but the sample's target analytes were not detected above the maximum allowable concentrations in Table 3.1 for the analytes in the sample
Q1	Sample integrity was not maintained - Q1
Q2	The sample is heterogeneous, and sample homogeneity could not be readily achieved using routine laboratory practices - Used to denote that the sample as-received could not be fully pre-homogenized in packaging prior to microbiology analysis
Q3	Testing result is for informational purposes only and cannot be used to satisfy dispensary testing requirements in R9-17-317.01(A) or labeling requirements in R9-17-317

Notes and Addenda:



Bryant Kearl
Chief Scientific Officer
07/08/2026

Confident LIMS
All Rights Reserved
coa.support@confidentlims.com
(866) 506-5866
www.confidentlims.com



ARIZONA DEPARTMENT OF HEALTH SERVICES' WARNING:

Marijuana use can be addictive and can impair an individual's ability to drive a motor vehicle or operate heavy machinery. Marijuana smoke contains carcinogens and can lead to an increased risk for cancer, tachycardia, hypertension, heart attack, and lung infection. Marijuana use may affect the health of a pregnant woman and the unborn child. Using marijuana during pregnancy could cause birth defects or other health issues to your unborn child;

KEEP OUT OF REACH OF CHILDREN.

The product associated with the COA has been tested by Apollo Labs using validated state certified testing methodologies as required by Arizona state law. Values reported herein relate only to the specific sample of product submitted by Client for testing. Apollo Labs makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levels of any compounds reported herein. This Certificate shall not be reproduced except in full, without the written approval of Apollo Labs. Testing results were obtained according to requirements in the quality assurance plan in R9-17-404.05, in the applicable standard operating procedure, and in R9-17-404.03 or R9-17-404.04.

C. Berriez

Sample ID: 2607APO3069.15280

Strain: C. Berriez

Matrix: Plant

Type: Flower - Cured

Source Batch #:

Collected: 07/03/2026 07:32 am

Received: 07/03/2026

Completed: 07/08/2026

Batch #: 1485.C.BERRIEZ

Harvest Date: 07/01/2026

Client

Tru Med

Lic. # 00000079DCUU00478781

Lot #:

Production/Manufacture Date:

Production/Manufacture Method: Indoor

Customer Supplied Information:



[Signature]

Bryant Kearl
Chief Scientific Officer
07/08/2026

Confident LIMS
All Rights Reserved
coa.support@confidentlims.com
(866) 506-5866
www.confidentlims.com



ARIZONA DEPARTMENT OF HEALTH SERVICES' WARNING:

Marijuana use can be addictive and can impair an individual's ability to drive a motor vehicle or operate heavy machinery. Marijuana smoke contains carcinogens and can lead to an increased risk for cancer, tachycardia, hypertension, heart attack, and lung infection. Marijuana use may affect the health of a pregnant woman and the unborn child. Using marijuana during pregnancy could cause birth defects or other health issues to your unborn child;

KEEP OUT OF REACH OF CHILDREN.

The product associated with the COA has been tested by Apollo Labs using validated state certified testing methodologies as required by Arizona state law. Values reported herein relate only to the specific sample of product submitted by Client for testing. Apollo Labs makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levels of any compounds reported herein. This Certificate shall not be reproduced except in full, without the written approval of Apollo Labs. Testing results were obtained according to requirements in the quality assurance plan in R9-17-404.05, in the applicable standard operating procedure, and in R9-17-404.03 or R9-17-404.04.